Springworks Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
SpringWorks Therapeutics highlights its commercial progress with OGSIVEO and GOMEKLI, along with ongoing clinical development and strategic partnerships in its 2024 10-K filing.
SpringWorks Therapeutics details its authorized capital stock, common and preferred stock rights, and anti-takeover provisions in its recent 10-K filing.